Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Total HBV / HDV Franchise by Year
Total HBV / HDV Franchise (legacy sub-franchise breakout) ($M) ($M)
Gilead Sciences Total HBV / HDV Franchise: $1,017M in FY2023, up 2.9% from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
Source: Form 10-K (filed 2024-02-23) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total HBV / HDV Franchise (legacy sub-franchise breakout) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 1,017 | +2.9% | Form 10-K (filed 2024-02-23) ↗ |
| FY2022 | Dec 31, 2022 | 988 | +2.0% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 969 | +12.7% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 860 | +15.9% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 742 | – | Form 10-K (filed 2022-02-23) ↗ |
Breakdown
What makes up total HBV / HDV Franchise
- Total HBV / HDV Franchise (legacy sub-franchise breakout) — U.S. sales ($M)418 · FY2023
- Total HBV / HDV Franchise (legacy sub-franchise breakout) — Europe sales ($M)133 · FY2023
- Total HBV / HDV Franchise (legacy sub-franchise breakout) — Rest of World sales ($M)466 · FY2023
- Total HBV / HDV Franchise (legacy sub-franchise breakout) — Worldwide YoY growth (%)2.0% · FY2022
- Viread (tenofovir disoproxil fumarate — legacy breakout) ($M)83 · FY2023
- Other HBV / HDV (Hepcludex / Hepsera — legacy breakout) ($M)72 · FY2023
Cite this data
StockData. (2026). Gilead Sciences Total HBV / HDV Franchise ($M), annual FY2019–FY2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-hbv-hdv-total
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.